HIV Scientific Papers
HIV-1 Non-Group M Phenotypic Susceptibility to Ibalizumab
2022
L. Poisson-Arnaud, Quentin le Hingrat, JC Plantier and E Alessandri-Gradt
Efficacy, pharmacokinetics, and safety over 48 weeks with ibalizumab-based therapy in treatment-experienced adults infected with HIV-1: a phase 2a study.
2021
J Acquir Immune Defic Syndr.
Gathe JC, Hardwicke RL, Garcia F, et al.
86(4):482-489.
Assessment of genotypic patterns associated with HIV-1 sensitivity to ibalizumab [abstract].
2020
Reviews in Antiviral Therapy & Infectious Diseases.
Jullien H, Leonard M, Cash RB, et al.
7:27. Proceedings of the European Meeting on HIV & Hepatitis 2020.
Assessment of genotypic patterns associated with HIV-1 sensitivity to ibalizumab.
2020
Jullien H, Leonard M, Cash RB, et al.
Poster #27 presented at: European Meeting on HIV & Hepatitis 2020; October 28-30 2020; virtual.
Long-term efficacy, safety, and durability of ibalizumab-based regimens in subgroup of TMB-202 participants [abstract].
2020
Open Forum Infect Dis.
Towner W, DeJesus E, Schrader S, et al.
7(suppl 1):S542–S543. Proceedings of IDWeek, 2020.